- Research article
- Open Access
An improved method of delivering a sclerosing agent for the treatment of malignant pleural effusion
BMC Cancer volume 19, Article number: 614 (2019)
Malignant pleural effusion (MPE) is a devastating sequela associated with cancer. Talc pleurodesis is a common treatment strategy for MPE but has been estimated to be unsuccessful in up to 20–50% of patients. Clinical failure of talc pleurodesis is thought to be due to poor dispersion. This monograph reports the development of a foam delivery system designed to more effectively coat the pleural cavity.
C57BL/6 mice were injected with Lewis lung carcinoma (LL/2) cells intrapleurally to induce MPE. The mice then received either normal saline (NS) control, foam control (F), talc slurry (TS, 2 mg/g) or talc foam (TF, 2 mg/g). Airspace volume was evaluated by CT, lungs/pleura were collected, and percent fibrosis was determined.
The TF group had significantly better survival than the TS group (21 vs 13.5 days, p < 0.0001). The average effusion volume was less in the talc groups compared to the control group (140 vs 628 μL, p < 0.001). TF induced significant lung fibrosis (p < 0.01), similar to TS. On CT, TF significantly (p < 0.05) reduced loss of right lung volume (by 30–40%) compared to the control group. This was not seen with TS (p > 0.05).
This report describes using a novel talc foam delivery system for the treatment of MPE. In the LL/2 model, mice treated with the TF had better survival outcomes and less reduction of lung volume than mice treated with the standard of care TS. These data provide support for translational efforts to move talc foam from animal models into clinical trials.
Cancer is the second leading cause of death in the United States [1, 2], with primary lung cancer as the most common cause of cancer deaths, and death from all sources of cancer typically associated with uncontrolled metastases. Both primary lung tumors and lung metastases originating from other primary sites commonly induce a process known as malignant pleural effusion (MPE) . MPE affects up to 15% of patients with cancer, and the number of patients afflicted with this complication is estimated to continue to rise as more patients experience increased overall survival with cancer, due to the availability of more effective therapies . It is not entirely clear what factors determine whether MPE develops in individual patients, with more work required. Mechanistic investigations to date have associated MPE with both genomic changes (e.g., KRAS mutations) and immunological factors (e.g., mast cells, and immune cell-associated NF-kB signaling and TNF-alpha secretion) [5,6,7,8]. MPE is associated with worse prognosis, and patients that develop MPE have a median survival of four to 7 months [9, 10].
The pathophysiology of MPE primarily reflects vascular leakiness that results in fluid accumulation in the pleural cavity between the visceral pleura covering the lungs and the parietal pleura covering the internal aspect of the chest wall. The majority of patients suffering from MPE eventually develop dyspnea at rest , a significant factor in reducing their quality of life (QoL). Dyspnea develops due to compression of the lung and impaired diaphragmatic and chest wall movement [4, 9]. Symptomatic MPEs that do not respond to treatment of the underlying disease require palliative therapy directed at the pleural space. Treatment of MPE predominantly aims to relieve dyspnea and improve the patient’s overall QoL in the least invasive manner possible . Typically, this is done by inducing pleurodesis (scarring) to reduce the pleural volume available for fluid accumulation. Recent work has shown that talc slurry delivered through an indwelling catheter generated successful pleurodesis in 43% of patients , although reported success rates vary significantly, from a low of 40% to as high as 70–80% [13,14,15]. In the absence of any better approaches, there is need to reduce variability and increase overall effectiveness of this technique.
This study uses a novel thermosensitive hydrogel talc foam (TF) designed to more effectively coat the pleural cavity and thereby provide more durable and more reliable chemical pleurodesis. We use an immunocompetent mouse model of MPE [5, 6, 16, 17] to evaluate whether a TF delivery system is an improved method of delivering talc for the treatment of MPE. The primary aim of this study is to investigate whether TF delivery to the pleural cavity is effective, and whether TF is a viable treatment option for MPE.
Lewis lung carcinoma (LL/2) cells transduced with LV-Fluc-P2A-Puro (identifier: LL/2-Fluc-Puro) were purchased in 2018 directly from Imanis Life Sciences (Rochester, MN, USA), who authenticate the cell lines prior to shipment. The cell line was tested for mouse pathogens prior to use and were negative. LL/2 cells are mouse cells and do not require ethical approval. Cells were cultured at 37 °C in 5% CO2 using DMEM supplemented with 10% fetal bovine serum, 1x Penicillin/Streptomycin and 2 μg/mL puromycin.
Foam, talc foam (TF) and talc slurry (TS)
The foam delivery system is comprised of a triblock copolymer  hydrogel (Fig. 1a) in a saline solution that exhibits a reverse thermosensitive viscosity profile. A liquid at room temperature, the hydrogel undergoes a sol-gel transition at temperatures greater than ~ 25 °C (Fig. 1b). When foamed by agitating the cooled liquid hydrogel with air, the resultant foam is a thin liquid. At physiological temperatures, the foam rapidly collapses and forms a viscous, sticky gel.
The cooled liquid was loaded into a 10 cc syringe and aerated using a Disofix three-way stopcock (B. Braun Medical Inc., Bethlehem, PA) and a second 10 cc syringe filled with air at a 1:1 ratio of air and liquid. Foam was generated by mixing the air and gel through the three-way stopcock until the desired consistency of foam was obtained. The foam was freshly prepared shortly before injection and kept on ice until immediately before each injection.
For the talc foam, the above-mentioned cooled liquid was combined with talc (powder, 10 μm, Millipore-Sigma) within a 10 cc syringe, to achieve a concentration of 2 mg talc per gram of mouse body weight (2 mg/g). The mixture was aerated using a 1:1 ratio of air and the gel-talc mixture, to generate TF.
TS was prepared as previously described [19, 20] to a final concentration of 2 mg/g. In brief, talc was mixed with sterile saline using two 10 cc syringes connect via a three-way stopcock. TS was freshly prepared shortly before injection and kept on ice until right before each injection.
Rheological studies of the triblock copolymer hydrogel (Fig. 1b) were performed on a DHR-3 rheometer, TA Instruments (Calumet, MI) using parallel plates, 40 mm in diameter, with a gap of 1 mm. A Peltier system was used to perform temperature ramps by heating the plates and all data were collected in the linear regime of the amplitude. A thin layer of silicone oil was added surrounding the plates to prevent evaporation during the experiment. A heating rate of 1.45 °C/min was used. The complex modulus, G*, storage modulus, G’, and loss modulus G”, were measured for each of the formulations. The complex modulus is related to the storage modulus and loss modulus by equation 1 (Eq. 1).
Computer tomographic (CT) imaging and quantitative analysis
Mice were anesthetized with 2% isoflurane in O2 for induction and were then maintained in 0.5% isoflurane during the scan. Scanning was performed with a Sofie Biosciences CT/PET machine (G8 PET/CT, PerkinElmer/Sofie Biosciences, Culver City, CA) using the standard protocol specified by the manufacturer. To calculate airspace volume, VivoQuant software (inviCRO, Boston, MA) was used. To identify the total area of air-filled lung, areas with minimal contrast within a specific range, were automatically highlighted using the Connected Thresholding function. This setting was kept consistent for all analyzed mice. The airspace volume was calculated automatically in mm3. Trachea and other artifacts were excluded manually. Mice were scanned immediately after the injection of tumor cells and again at the end of the experiment. The pre-injection scan for each mouse served as the reference scan used to calculate the remaining lung volume for each treatment.
All animal care and experimental procedures were prospectively approved by the Fox Chase Cancer Center Institutional Animal Care and Use Committee (IACUC). The Fox Chase Cancer Center staff tended to the mice daily and for the duration of the experiment. 6–8-week-old male and female C57BL/6 mice (obtained from The Jackson Laboratory, Bar Harbor, ME) were acclimatized for 1 week before use.
To first assess TF as a sclerosing agent, mice without tumors were randomly assigned into one of the following groups: control (foam or saline), TF, or TS. For the TS group or for TF (prepared as described above), the volume injected was adjusted based on body weight, to achieve a final injected dose of 2 mg talc per gram mouse body weight. The volume for foam or saline was calculated to match the volumes used for the talc treatment group. Talc mixtures (TF or TS) were then injected intrapleurally into the right pleural cavity. Mice were anesthetized with isoflurane and the right chest was cleaned with an alcohol solution. A 23-gauge needle attached to a 1 mL syringe was introduced into the right chest cavity at 1 cm lateral to the right parasternal line, as previously described . The mice were euthanized 7 days post-treatment, and the chest cavity was evaluated for fibrosis as described below.
To generate MPE, intrapleural injection of LL/2 cells was performed. Mice were anesthetized with 1–3% isoflurane gas and the right chest was cleaned with an alcohol solution. A 23-gauge needle attached to a 1 mL syringe containing 1.5 × 105 of LL/2 cells in sterile PBS was introduced into the right chest cavity at 1 cm lateral to the right parasternal line. The needle was slowly advanced until it reached the pleural space. The cell suspension was then carefully injected. All mice were monitored until completely recovered from the procedure. Four days after the injection of LL/2 cells, all mice were randomly assigned into one of the following groups: control (foam or saline), TF, or TS, each of which were injected as described in the previous paragraph.
For effusion and survival analyses, mice were injected with LL/2 cells as described above, then underwent CT imaging 1 day and 14 days after the injection of cells, to assess lung volume status. Four days after the injection of cells, all mice were randomly assigned to receive intrapleural control foam/saline, TF, or TS, at the appropriate concentration and volume as noted above. The mice were euthanized (CO2 inhalation) according to the approved IACUC protocol upon showing signs of poor health, presentation with signs of pain or distress, or if they experienced a rapid loss of weight (> 20% of body weight over 7 days).
Immediately following euthanasia, the abdominal wall of the mice was opened, and the viscera were retracted to visualize the diaphragm, which was punctured with a 23-gauge needle to aspirate pleural fluid. The pleural fluid volume was measured. The thorax was dissected and removed en bloc. All lungs were imaged and collected for histology. Lungs were fixed in 10% phosphate-buffered formaldehyde for 24–48 h, dehydrated by incubation in ethanol followed by xylene (70% ethanol, 3 h; 95% ethanol, 2 h; 100% ethanol, 2 h; ethanol-xylene, 1 h; xylene, 3 h) then embedded in paraffin. 5 μm thick slices were cut, mounted on slides and stained with trichrome. Stained slides were scanned with Vectra 2.3 Automated Quantitative Pathology Imaging System (Perkin Elmer, Waltham, MA). Tissue segmentation (% fibrosis) was determined by automated quantitative analysis using InForm software (PerkinElmer Inc., Waltham, MA).
For all experiments indicated, p values were calculated using one-way ANOVA (GraphPad Prism version 6.00 for Mac; GraphPad Software) or Student’s t test as specified. Survival curves were generated using the Kaplan and Meier method and tested for significance using log-rank tests.
In justification of animal number in experimental cohorts, we would set the Type I error rate to 5%/3 = 1.67% Type I error (2-sided). In this case with a relatively small number of multiple comparisons, the Bonferroni correction sets the p-value to a level that is more generous than using a 1% False Discovery Rate (FDR). With 10 animals per cohort, we would have 85% power to detect a standardized effect of 1.7 standard deviation units. We used generalized linear models (GLMs) for analysis, assuming normal distribution and identity link.
Talc foam is an effective sclerosing agent
We evaluated the sclerosing potential of talc foam (TF; Fig. 1), which transitions from liquid to gel at temperatures above 29 °C, in comparison with talc slurry (TS), foam (F), or saline (S). Analysis of trichrome stained lung tissue from mice after intrapleural injection with S, F, TS, or TF revealed significant fibrosis in the lungs of mice receiving TS or TF (Fig. 2a). Fibrosis quantified by Vectra from trichrome-positive tissue ranged from 0.19 to 21.4% of the total lung volume across all groups. Fibrosis averaged 6–7% of the lung in mice receiving TF, versus 8% in those receiving TS; a statistically insignificant difference. Importantly, the percent fibrosis was significantly higher in the TF (p < 0.05) and TS (p < 0.01) groups compared to the lung fibrosis detected for S- or F- treated mice (Fig. 2b).
Talc foam reduces loss of lung volume
As a model to evaluate TF effectiveness for MPE, mice were injected with LL/2 cells into the right pleural cavity as described in the methods section. All mice underwent CT imaging 1 day after the injection, without any significant difference noticed between mice (data not shown). The mice were then randomly selected to receive control S or F, TF, or TS, in the right pleural cavity, which was administered 4 days after the injection of LL/2 cells, followed by re-imaging at day 10 (Fig. 3a). CT imaging of the lungs of euthanized mice indicated that TF talc foam effectively reduced loss of lung volume (Fig. 3b). Quantification of CT data demonstrated that TF significantly (p < 0.05) reduced loss of right lung volume (by 30–40%) compared to the loss of lung volume in the control group. This was not seen in the TS group (p > 0.05; Fig. 3c). No differences between the left lung volume was observed for the three groups (Fig. 3c).
Talc foam reduces MPE volume and provides superior survival compared to talc slurry
To evaluate if TF influenced survival outcomes, mice were injected with LL/2 cells in the right pleural space as described above, and randomly assigned to treatment with S, F, TF, or TS. They were then observed until signs of distress appeared, and euthanized. The TF group and both the F and S control groups had similar median survival durations (21 days and 22 days, respectively), without a statistically significant difference. However, mice treated with the standard of care TS, compared to the other two groups, had significantly reduced overall survival of only 13.5 days (p < 0.0001; Fig. 4a).
Following euthanasia, the effusion volume was directly measured for each mouse. Mice in the control groups had an average effusion volume of 627.5 μL. In contrast, the average effusion volumes for TS treated mice and TF treated mice were 155.7 μl and 140.0 μl, respectively (Fig. 4b). The difference in effusion volume between both the TS- and TF- treated cohorts versus the control group was statistically significant (p < 0.001). No significant difference was detected between these two treatment groups.
Managing MPEs presents one of the greatest treatment challenges of cancer-associated complications. In the US alone, an estimated 150,000 patients develop MPE annually . Talc slurry pleurodesis can provide significant relief to patients with MPE; however, the incomplete effectiveness of chemical pleurodesis [13,14,15] is not ideal, while alternatives such as indwelling pleural catheters can interfere with a patient’s QoL due to infection, cellulitis and catheter tract metastasis [22, 23]. The talc foam described in this monograph presents a novel means of delivering a sclerosing agent more effectively to the pleural space of mice and could potentially provide improved outcomes for patients afflicted with malignant pleural effusions.
In this study, a previously described mouse model of MPE [5, 6, 16, 17] was used to test the efficacy of a novel foam delivery system designed to improve the dispersal of agents injected into the pleural space. Talc was successfully delivered into the pleural space and established fibrotic changes detected by trichrome staining, similar to fibrosis induced using the standard of care talc slurry. Intriguingly, talc foam significantly prevented loss of air volume, compared to the control treatment, which was not the case for the talc slurry. This difference is likely due to improved dispersion of the foam within the pleural cavity. Talc foam did not adversely affect survival compared to the control group, and demonstrated significantly better survival compared to conventional pleurodesis. The reduction in survival between the different treatment groups is again likely a result of the poor distribution of the talc slurry, which may have caused cardiovascular compromise due to more focused pressure on the heart. Further studies are needed to explore these observed survival differences. However, it is unlikely that these findings would translate to the clinic, given that chemical pleurodesis has not been shown to negatively impact survival, but rather improves quality of life. Additionally, talc foam reduced effusion volumes substantially. The amount of pleural effusion was not significantly different between the TS and the TF groups (Fig. 4), making it less likely that the effusion volume was a significant confounding factor on the loss of right lung volume. The perhaps most critical aspect of treating MPE is effective reduction of the effusion, given that dyspnea is the most common symptom of MPE . These results suggest that foam delivery of talc is safe and effective and proposes that TF would perform as well if not better in the clinic than the standard of care TS.
The novel foam delivery system described in this study presents an entirely new potential platform for efficient intrapleural treatment delivery beyond talc pleurodesis that may also be helpful in controlling MPE. For example, recent work has demonstrated that anti-EGFR and anti-VEGF drugs administered intrapleurally can reduce effusion volume and inflammatory mediators in pleural fluid and thereby decrease morbidity due to MPE . It is also known that KRAS mutation-driven CCL2 and HSP90/IKKα/IKKβ regulated IL-1β signaling clearly plays a role in the development of MPE [5, 6, 8]. An interesting next step would be evaluation of intrapleural delivery by foam delivery of therapeutic agents such as anti-EGFR and anti-VEGF drugs, HSP90 inhibitors [25, 26] and bortezomib  to inhibit HSP90/IKKα/IKKβ activity. Therefore, efficient delivery and intrapleural dispersion of a variety of therapeutic agents could significantly improve how MPEs are managed. Future studies will focus on using foam delivery to achieve favorable dispersion at therapeutic concentrations of different sclerosing and therapeutic agents within the pleural space in animal models as well as in clinical studies. This approach has the potential to alter the clinical course for many cancer patients and improve their quality of life.
Reverse thermosensitive hydrogel foam delivery of talc is an effective way of treating MPE in an established mouse model [5, 6, 16, 17]. MPE is a devastating sequela of cancer and additional therapeutic approaches are desperately needed. The findings discussed in this report provide the foundation for future studies of talc foam in more clinically relevant settings as well as for future explorations of intrapleural delivery of different therapeutic agents. The role of pleurodesis and the need for additional sclerotic agents may increase further as immunotherapies continue to improve overall and progression free survival of cancer patients [27,28,29,30]. Our findings lay the foundation for advanced translational clinical studies of talc foam, to further investigate the potential this treatment holds for improving the QoL of patients suffering from MPE.
Availability of data and materials
All data is included as part of the manuscript or as part of the supplemental materials section.
Analysis of variance
Chemokine (C-C motif) ligand 2
Epidermal growth factor receptor
False discovery rate
Generalized linear models
Heat shock protein 90
Institutional Animal Care and Use Committee
Iκb kinase α
IκB kinase β
Interleukin 1 beta
Kirsten Rat Sarcoma Viral Proto-Oncogene
Lewis lung carcinoma
Malignant pleural effusion
Nuclear factor kappa-light-chain-enhancer of activated B cells
Positron emission tomography/computer tomography
Quality of life
Tumor necrosis factor-α
Vascular endothelial growth factor
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
Golemis EA, Scheet P, Beck TN, Scolnick EM, Hunter DJ, Hawk E, Hopkins N. Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev. 2018;32(13–14):868–902.
Feller-Kopman D, Light R. Pleural disease. N Engl J Med. 2018;378(18):1754.
Clive AO, Jones HE, Bhatnagar R, Preston NJ, Maskell N. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev. 2016;(5):CD010529. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010529.pub2/abstract.
Agalioti T, Giannou AD, Krontira AC, Kanellakis NI, Kati D, Vreka M, Pepe M, Spella M, Lilis I, Zazara DE, et al. Mutant KRAS promotes malignant pleural effusion formation. Nat Commun. 2017;8:15205.
Marazioti A, Lilis I, Vreka M, Apostolopoulou H, Kalogeropoulou A, Giopanou I, Giotopoulou GA, Krontira AC, Iliopoulou M, Kanellakis NI, et al. Myeloid-derived interleukin-1beta drives oncogenic KRAS-NF-kappaBeta addiction in malignant pleural effusion. Nat Commun. 2018;9(1):672.
Stathopoulos GT, Kollintza A, Moschos C, Psallidas I, Sherrill TP, Pitsinos EN, Vassiliou S, Karatza M, Papiris SA, Graf D, et al. Tumor necrosis factor-alpha promotes malignant pleural effusion. Cancer Res. 2007;67(20):9825–34.
Giannou AD, Marazioti A, Spella M, Kanellakis NI, Apostolopoulou H, Psallidas I, Prijovich ZM, Vreka M, Zazara DE, Lilis I, et al. Mast cells mediate malignant pleural effusion formation. J Clin Invest. 2015;125(6):2317–34.
Feller-Kopman D, Light R. Pleural disease. N Engl J Med. 2018;378(8):740–51.
Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology. 2015;20(4):654–9.
Feller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, Iyer NP, Lee YCG, Lewis SZ, Maskell NA, et al. Management of Malignant Pleural Effusions. An official ATS/STS/STR clinical practice guideline. Am J Respir Crit Care Med. 2018;198(7):839–49.
Ost DE, Niu J, Zhao H, Grosu HB, Giordano SH. Quality gaps and comparative effectiveness of management strategies for recurrent malignant pleural effusions. Chest. 2018;153(2):438–52.
Bhatnagar R, Keenan EK, Morley AJ, Kahan BC, Stanton AE, Haris M, Harrison RN, Mustafa RA, Bishop LJ, Ahmed L, et al. Outpatient talc administration by indwelling pleural catheter for malignant effusion. N Engl J Med. 2018;378(14):1313–22.
Dresler CM, Olak J, Herndon JE 2nd, Richards WG, Scalzetti E, Fleishman SB, Kernstine KH, Demmy T, Jablons DM, Kohman L, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127(3):909–15.
Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur J Cardiothorac Surg. 2018;52(1):1–23.
Stathopoulos GT, Kalomenidis I. Animal models of malignant pleural effusion. Curr Opin Pulm Med. 2009;15(4):343–52.
Acencio MM, Puka J, Marchi E, Antonangelo L, Terra RM, Vargas FS, Capelozzi VL, Teixeira LR. A modified experimental model of malignant pleural disease induced by lung Lewis carcinoma (LLC) cells. J Transl Med. 2015;13:302.
Rehman K, Chen S. Natural and synthetic polymers as drug carriers for delivery of therapeutic proteins AU - Hamid Akash, Muhammad Sajid. Polym Rev. 2015;55(3):371–406.
Marchie E, Vargas FS, Acencio MMP, Teixeira LR, Antonangelo L, Lee YCG, Light RW. Pleurodesis: A novel experimental model. Respirology. 2007;12(4):500–4.
Iwasaki Y, Takamori S, Mitsuoka M, Kashihara M, Nishi T, Murakami D, Matsumoto R, Mifune H, Tajiri Y, Akagi Y. Experimental validation of talc pleurodesis for carcinomatous pleuritis in an animal model. Gen Thorac Cardiovasc Surg. 2016;64(7):409–13.
Fortin M, Tremblay A. Pleural controversies: indwelling pleural catheter vs. pleurodesis for malignant pleural effusions. J Thorac Dis. 2015;7(6):1052–7.
Lui MM, Thomas R, Lee YC. Complications of indwelling pleural catheter use and their management. BMJ Open Respir Res. 2016;3(1):e000123.
Davies HE, Mishra EK, Kahan BC, Wrightson JM, Stanton AE, Guhan A, Davies CW, Grayez J, Harrison R, Prasad A, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012;307(22):2383–9.
Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: from bench to bedside. Eur Respir Rev. 2016;25(140):189–98.
Acencio MMP, Puka J, Alvarenga VA, Martins V, de Carvalho MLP, Marchi E, Capelozzi VL, Teixeira LR. Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion. Oncotarget. 2017;8(62):105093–102.
Beck TN, Korobeynikov VA, Kudinov AE, Georgopoulos R, Solanki NR, Andrews-Hoke M, Kistner TM, Pepin D, Donahoe PK, Nicolas E, et al. Anti-Mullerian hormone signaling regulates epithelial plasticity and Chemoresistance in lung Cancer. Cell Rep. 2016;16(3):657–71.
Proia DA, Bates RC. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. Cancer Res. 2014;74(5):1294–300.
Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med. 2016;375(19):1823–33.
Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, et al. First-line Nivolumab in stage IV or recurrent non-small-cell lung Cancer. N Engl J Med. 2017;376(25):2415–26.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–56.
The authors would like to thank the facilities and our colleagues at Fox Chase Cancer Center and at Drexel University College of Medicine. We would also like to thank Dr. Joy Baxter for assisting with the rheology and critique of the manuscript.
The authors were supported by the Ruth L. Kirschstein National Research Service Award F30 fellowship (F30 CA180607) from the National Institutes of Health (to T.N.B.), NCI Core Grant P30 CA006927 (to Fox Chase Cancer Center), NIH R01 CA218802, NIH R21 CA223394, V Foundation translation award program T2018–013, and a Fox Chase Cancer Center 2018 pilot protocol grant (to Y.B.); NIH R01 DK108195 (to E.A.G.) ; and by the Russian Government Program for Competitive Growth of Kazan Federal University and by Russian Science Foundation grant № 18–75-00104 (to A.Y.D.). The funding was used to support laboratory experiments, data analysis and cover publication fees.
Ethics approval and consent to participate
All animal care and experimental procedures were prospectively approved by the Fox Chase Cancer Center Institutional Animal Care and use Committee (IACUC).
Consent for publication
Y.B. has served on advisory boards of AbbVie, Astra Zeneca and Caris, and declares no COI. GWL is a founder and a major shareholder in TDL Innovations, LLC. TDL Innovations, LLC is developing therapeutic approaches to treat MPE. E.G. and Y.B. are on the BMC Cancer editorial board. The other authors have no competing interests to disclose.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Beck, T.N., Deneka, A.Y., Chai, L. et al. An improved method of delivering a sclerosing agent for the treatment of malignant pleural effusion. BMC Cancer 19, 614 (2019). https://doi.org/10.1186/s12885-019-5777-z
- Lung cancer
- Metastatic cancer
- Malignant pleural effusion
- Mouse model
- Sclerosing agent
- Thermosensitive hydrogel